Generated by AI
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous insulin infusion. The company also markets Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension, extending its presence in specialty respiratory care. MannKind Corporation serves patients and healthcare providers across endocrine and lung disease markets, with products designed to address chronic conditions that require convenient, patient-centered treatment options. Headquartered in Danbury, Connecticut, MannKind Corporation operates as a focused healthcare business centered on innovative drug delivery and disease management solutions.
Website1 Casper Street
Danbury, CT, 06810
United States
The latest articles about MNKD.
Analyst rates MannKind a Hold: Q3 revenue rose 24% to $101.87 million, while repeat demand is unproven and dilution may come before positive cash flow.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about MNKD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.